Jazz Pharmaceuticals JAZZ Other liabilities
Other liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other liabilities?
- Jazz Pharmaceuticals (JAZZ) reported other liabilities of $12.2M in Q1 2026.
- How has Jazz Pharmaceuticals's other liabilities changed year-over-year?
- Jazz Pharmaceuticals's other liabilities increased by 320.7% year-over-year, from $2.9M to $12.2M.
- What does other liabilities mean?
- The change in miscellaneous short-term debts or obligations not classified elsewhere.
- How do you interpret other liabilities?
- Large fluctuations may indicate changes in deferred revenue recognition or specific non-recurring operational liabilities.
- How does other liabilities compare across companies?
- Varies by company accounting practices; usually a small component of total liabilities.